Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Head and Neck Neoplasms 3Carcinoma, Hepatocellular 3Neoplasms 2Melanoma 2Lymphoma, B-Cell, Marginal Zone 2Urinary Bladder Neoplasms 1Sarcoma 1Prostatic Neoplasms 1NSCLC 1Lymphoma, Non-Hodgkin 1Lymphedema 1Leukemia, Myeloid, Chronic-Phase 1Gynecological Cancers 1Fibrosis 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Squamous Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Ductal, Breast 1Breast Neoplasms 1BRAF V600 Colorectal Cancer 1Anxiety Disorders 1Adenomatous Polyposis Coli 1

Interventions

Carboplatin 7Pemetrexed 6osimertinib 5Drug Therapy 5aflutinib 4tislelizumab 3anlotinib 3Radiotherapy 3Radiosurgery 3Paclitaxel 3Cisplatin 3toripalimab 2pembrolizumab 2camrelizumab 2apatinib 2Surgical Procedures, Operative 2S 1 (combination) 2HM781-36B 2Chemotherapy, Adjuvant 2Chemoradiotherapy 2trilaciclib 1surufatinib 1sintilimab 1rezivertinib 1lenvatinib 1icotinib 1famitinib 1envafolimab 1dacomitinib 1cemiplimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × NSCLC × Pharmaceutical Preparations × Clear all
NCT04318938 2026-03-02

Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping

Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest

Phase 2 Active not recruiting
118 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡